Sandu Pharmaceuticals (524703) Q3 24/25 earnings summary

Executive summary

• Board approved unaudited standalone financial results for the quarter ended 31st December 2024.

• No consolidation required from this quarter due to sale of entire stake in Sandu Phytoceuticals Private Limited.

• Appointment of new internal auditors for Goa and Mumbai operations for FY 2025-26.

• Resignation of Smt. Shubhada Sandu as Non Executive Non Independent Director due to health and age.

Financial highlights

• Revenue from operations for Q3 FY25 was ₹1,837.29 lakhs, up from ₹1,742.87 lakhs in Q3 FY24.

• Net profit for Q3 FY25 stood at ₹55.55 lakhs, compared to ₹20.70 lakhs in Q3 FY24.

• Total comprehensive income for Q3 FY25 was ₹73.80 lakhs, up from ₹34.45 lakhs in Q3 FY24.

• EPS for Q3 FY25 was ₹0.57, compared to ₹0.21 in Q3 FY24.

• For the nine months ended Dec 2024, revenue was ₹5,312.32 lakhs and net profit was ₹122.25 lakhs.

Outlook and guidance

• Company will report only standalone results going forward due to divestment of subsidiary.

• Management continues to focus on Ayurvedic Property Medicines as the sole business segment.